Article

Nerve growth factor level may be marker for neurogenic overactive bladder, interstitial cystitis

Author(s):

Penny Allen

Nerve growth factor (NGF) levels in urine could prove a useful biomarker for interstitial cystitis/painful bladder syndrome (IC/PBS) and neurogenic overactive bladder.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Andrea Pezzella, MD, URPS, FACOG, answers a question during a Zoom video interview
Andrea Pezzella, MD, URPS, FACOG, discusses Neuspera’s SNM device
Ashley Winter, MD, calls for label update on low-dose vaginal estrogen
Ashley Winter, MD, calls for label update on low-dose vaginal estrogen
The ADVANCED-2 trial, TARA-002
The ADVANCED-2 trial, TARA-002
Unmet needs in high risk NMIBC
Unmet needs in high risk NMIBC
Joseph Song, MD, on the emergence of new suction-based devices for stone disease
Joseph Song, MD, on the emergence of new suction-based devices for stone disease
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES, answers a question during a Zoom video intervew
How eating disorders affect bladder and pelvic floor health
2 experts in this video
Fitting Oral ADT Options Into the Prostate Cancer Treatment Plans
2 experts in this video
The Current Landscape of ADT in Prostate Cancer
Daniel D. Joyce, MD, MS, answers a question during a Zoom video interview
Daniel D. Joyce, MD, MS, discusses the economics of trimodal therapy in MIBC
Sarah Razavi, MD, answers a question during a Zoom video interview
Sarah Razavi, MD, outlines strategies for mitigate surgeon discomfort during URS
Related Content
Study shows persistent bone protective effect of menopausal hormone therapy
July 25th 2025

Study shows persistent bone protective effect of menopausal hormone therapy

Hannah Clarke
Data showed that fracture risk rises briefly after menopausal hormone therapy discontinuation, then falls below never-users.
Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD
July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD
Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.
Aquablation procedures for prostate cancer completed at ambulatory surgery center
July 24th 2025

Aquablation procedures for prostate cancer completed at ambulatory surgery center

Hannah Clarke
The WATER IV PCa trial is comparing first-line Aquablation therapy with radical prostatectomy for the treatment of patients with localized prostate cancer.
Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD
June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD
Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.
FDA clears image-guided navigation platform for focal therapy in prostate cancer
July 23rd 2025

FDA clears image-guided navigation platform for focal therapy in prostate cancer

Hannah Clarke
The new advanced annotation workflow on the UroNav System is designed to work in tandem with DynaCAD Urology to support focal therapy planning.
Stethoscope with Pen, Charts and Graphs, Finance, Account, Statistics, Investment, Analytic Research Data Economy Spreadsheet and Business Company | Image Credit: © shahrilkhmd - stock.adobe.com
July 23rd 2025

Category III CPT code issued for Enhanced Lithotripsy System

Hannah Clarke
The code, 0991T, will become effective on January 1, 2026.
© 2025 MJH Life Sciences

All rights reserved.